An Open-Label, Single-Dose, Randomized, 3-Period, Crossover Study to Evaluate the Pharmacokinetic Dose Proportionality of Canagliflozin of 50, 100, and 300 mg Under Fasted Conditions in Healthy Subjects.
Phase of Trial: Phase I
Latest Information Update: 01 Jul 2015
At a glance
- Drugs Canagliflozin (Primary)
- Indications Obesity; Type 2 diabetes mellitus
- Focus Pharmacokinetics
- 09 Sep 2011 Actual end date Aug 2011 added as reported by ClinicalTrials.gov.
- 09 Sep 2011 Actual initiation date changed from Jun 2011 to May 2011 as reported by ClinicalTrials.gov.
- 09 Sep 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.